Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue$182.39M$182.39M+25.2% vs Q2 2023 Net Income$37.95M$37.95M+45.3% vs Q2 2023 EPS Diluted$0.73$0.73+49.0% vs Q2 2023 Gross Profit$95,166,000+30.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$69,109,000+25.8% Free Cash Flowderived$63,065,000+37.5% Margins · derivedGross margin52.2%+2.3 pt vs Q2 2023
Operating margin30.3%+5.0 pt vs Q2 2023
Net margin20.8%+2.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end